Page 1

RNS Number : 4695N Advanced Oncotherapy PLC 30 September 2021 30 September 2021 Prior to publication , the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation . With the publication of this announcement , this information is now considered to be in the public domain . Continued operational and financial advancements towards delivering the first fully operational LIGHT system with a 230MeV beam Further scientific research highlights superiority of LIGHT system Advanced Oncotherapy ( AIM : AVO ) , the developer of next - generation proton therapy systems for cancer treatment called LIGHT systems ( LIGHT ) , today announces its unaudited results for the six months ended 30 June 2021 . Key highlights : Significant progress made towards completing the first fully operational LIGHT system capable of accelerating protons at 230 MeV : Finished manufacturing of all critical hardware for the LIGHT system . Fully integrated medical software suite in place , providing customers with seamless user experience . Optimised installation process to enable quicker set - up of future LIGHT systems . LIGHT system capable of supporting a proton beam pulse every 5 milliseconds . The Company's target of delivering the first LIGHT system may still be achieved by the end of 2021 as previously communicated . However , due to external factors impacting the supply chain , such as the international shortage of semi - conductors and thermo - switches , this could slip into Q1 2022 . Study based on research from Mayo Clinic demonstrated the potential superiority of LIGHT in treating radio - resistant cancers . Signed a lessor financing partnership with Kineo Finance ( formerly known as DiaMedCare ) , providing potential customers with easier access to the Company's LIGHT system as it reduces the need for large initial upfront payments . Signed a letter of intent ( LOI ) with Saba Partners SAfor the proposed purchase of a three - treatment room LIGHT system inSwitzerland . Completed a c . £ 5.9 million equity fundraise which contributed towards progressing the LIGHT system's assembly , documentation , verification and validation activities . Post period end , announced the Company's largest fundraise to date comprising a subscription and issuance of shares to the value of 40 million , significantly bolstering the Company's balance sheet . Nicolas Serandour , CEO of Advanced Oncotherapy , said : " We are pleased with the Company's continued development which would not have been possible without the hard work and dedication of our staff . Despite the impact of Covid - 19 , we have made excellent progress towards the commissioning of a LIGHT system with a 230MeV beam . LIGHT's potential to be the leading proton therapy technology in the market was reinforced by the publication of a research study by the Mayo Clinic which further highlighted the potential advantages of LIGHT in comparison to other radiotherapy technologies and the need for proton therapy in treating cancers . ADVANCED ONCOTHERAPY PLC " We also recently strengthened our financial position following the announcement of the Company's largest equity fundraise to date , comprising a subscription and issuance of shares to the value of £ 40 million which are supporting us in the final steps of the assembly , documentation , verification and validation activities and the purchase of the remaining mponents of the LIGHT system in order to obtain regulatory approval of Advanced Oncotherapy's first LIGHT system . Notes for editors ( " Advanced Oncotherapy " or the " Company " ) Interim Results " In line with our strategy , we have also continued to develop partnerships with key stakeholders such akineo Finance and Saba Partners in order to support future sales of additional LIGHT systems . With Covid - 19 restrictions now being lifted , we remain confident with the Company's outlook and our ability to deliver the first LIGHT system . " Advanced Oncotherapy plc Dr. Michael Sinclair , Executive Chairman Nicolas Serandour , CEO Allenby Capital Limited ( Nomad and Joint Broker ) Nick Athanas / Liz Kirchner ( Corporate Finance ) Amrit Nahal / Matt Butlin ( Sales and Corporate Broking ) SI Capital Ltd ( Joint Broker ) Nick Emerson Jon Levinson www.avoplc.com Tel : +44 ( 0 ) 20 3617 8728 Tel : +44 ( 0 ) 20 3328 5656 Tel : +44 ( 0 ) 1483 413 500 Tel : +44 ( 0 ) 20 3871 4066 Page 1 of